Vayarin

DB09328Approved

Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children. Vayarin contains Lipirinen,... Vayarin contains Lipirinen, a proprietary composition containing phosphatidylserine-omega 3, EPA (eicosapentaenoic acid), and docosahexaenoic acid (DHA).

Mechanism
Curator reviewed · 4 references
Primary indication
ADHD in children, hypertriglyceridemia.Curator reviewed

What you can answer from here — as of April 02, 2025

29Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
17+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Vayarin, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account